The kidney in myeloma "The tube contains urine of very high specific gravity. When boiled it becomes slightly opaque. On the addition of nitric acid, it effervesces, assumes a reddish hue, and becomes quite clear; but as it cools, assumes the consistence and appearance which you see. Heat reliquefies it. What is it?"' So wrote Dr Thomas Watson in 1845 to Henry Bence Jones about the urine of Thomas Alexander McBean, drawing attention to one of the most characteristic abnormalities of multiple myeloma.
Over half of all patients with myeloma develop renal insufficiency and it is the second most common cause of death (after infection).23 A raised blood urea concentration at presentation is the single most important pointer to a poor prognosis.4
The causes of renal impairment in myeloma are many, and any one patient is unlikely to have a single cause. Those factors most usually mentioned include infection, hypercalcaemia, hyperuricaemia, hyperviscosity, Bence Jones proteinuria, Fanconi's syndrome, plasma cell infiltration of the kidney, amyloidosis, and glomerulosclerosis.S5
Renal failure is strongly associated with an excess of immunoglobulin light chains in the urine. Light chains are normally filtered by glomeruli and then reabsorbed and catabolised by cells in the proximal tubule-a physiological mechanism designed to deal with the small amounts of free light chain produced by normal people. The large amounts produced in myeloma, however, are toxic to renal tubular cells. In animals, injecting large amounts of light chain causes acute renal damage associated with the formation of casts and tubular atrophy,6 and studies of slices of rat kidney incubated with light chains have shown inhibition of the adenosine triphosphatase dependent sodium pump7 and of gluconeogenesis and metabolism of sodium iodohippurate in tubular cells. 8 Yet despite this toxicity some patients excrete large quantities of free light chains for long periods without any damage to their renal tubules.9 Apparently some light chains are more toxic than others. Two groups have shown that renal damage in myeloma correlates with the presence of urinary light chains with a high isoelectric point (pI).'°S uch light chains are more likely to precipitate in the acid urine of distal tubules to form casts; but atte-mpts to alkalise the urine with oral bicarbonate in a large series of patients had no effect on survival. 12 This finding may merely show the difficulty of alkalising the urine.
The casts in the urine of patients with myeloma are characteristic, having a waxy, lamiinated structure surrounded by reactive, syncytial giant cells, with occasional renal cells embedded in the matrix.'3 Such casts usually indicate renal failure,'3 and it was once thought that they caused the damage in myeloma kidney by obstructing individual nephrons.'4 As many as a third of patients with myeloma, however, have no kidney casts,55.'6 and they are more likely to be the consequence of renal damage than its cause.
The sequence of events in myeloma kidney begins with insidious damage to the proximal tubular cells by filtered light chains. This is present in virtually all patients with urinary light chain concentrations of over one unit per litre whether or not glomerular function is impaired. 7 As a result tubular reabsorption of light chains is reduced, increasing their final concentration in the urine. Tubular damage may be compounded by other factors such as hypercalcaemia, hyperuricaemia, and nephrotoxic antibiotics. Against this background individual episodes of dehydration and infection lead to tubular atrophy.5 As nephrons are lost each individual tubule carries an increasing load oflight chain resulting in the formation of casts-possibly -owing to the interaction of cationic light chains with the anionic Tamm-Horsfall mucoprotein. 6 Patients who present with renal failure commonly do so after a recent precipitating event, usually infection or dehydration. Prompt treatment with rehydration, antibiotics, and regimens to lower the calcium and urate concentrationstogether with short term dialysis if necessary will often restore renal function.'8 The eventual outcome depends on whether or not the tumour responds to chemotherapy.
In patients who have urinary light chains but who are not yet in renal failure a fluid intake ofthree litres a day is likely to prevent deterioration of renal function.'2 The exception to this happy prognosis is renal amyloidosis, which causes glomerular lesions; as well as interstitial damage. Although individual patients have responded to intensive chemotherapy,'920 in general even experimental treatments have been unsuccessful in this condition.2' Nevertheless, though systemic amyloidosis in myeloma is usually rapidly lethal, its progression is sometimes slow; it is well worth persevering with treating the myeloma and the renal failure with supportive measures short of long term dialysis. Most clinical applications of laser energy depend on the destructive effects produced by the absorbance of the laser energy in the target tissue. Clearly great care must be taken to avoid inadvertent exposure outside the target.
The American National Standards Institution established guidelines for the use of lasers in 1980,6 and these were followed by the British Standard Institution in 1983.7 Laser products are classified from 1 to 4 depending on the power output, only class 1 being inherently safe; classes 3 and 4 require medical surveillance. The concept of the maximum permitted exposure for direct. ocular exposure was introduced in terms of radiant exposure (Jim2) or irradiance (W/m2) at the cornea. This value.is well below (roughly two orders of magnitude) the level necessary-to produce an ophthalmoscopically visible retinal lesion within 24 hoursthe defined threshold lesion. Damage may, however, be produced at much lower levels, and the maximum permitted exposure should not be understood as marking the dividing line between safe and dangerous levels. The maximum permitted exposure for skin need not be so stringent.
A report produced by the DHSS last year stated that a "laser controlled area" should be established around any laser in use if there is any risk of the maximum permitted exposure being exceeded in that area. 8 The design of most ophthalmic lasers is such that the beam emerging from the laser tube is very well collimated. Passage of the beam through the delivery system alters this. Typically the laser is attached to a slit lamp or operating microscope and the beam is focused through an optical system converging towards a focal point and diverging thereafter. In some systems-for example, the endolasers used during vitreoretinal surgerydelivery is through a fibre optic and a diverging beam emerges. In both cases the beam irradiance will fall below the maximum permitted exposure at some distance from the delivery system. This distance, the nominal ocular hazard distance, is the crucial measure for any assessment of the protection of medical and paramedical staff working closely with lasers.
The DHSS guidelines for controlled areas imply that the nominal ocular hazard distance is known for each laser device. In practice, however, some manufacturers cannot supply this information, but a recent paper. has shown that it may be calculated with a relatively simple technique which is capable of precise results and is reproducible.9 In commonly encountered clinical settings the risk area may extend nearly 30 m from the delivery point. Usually, therefore, the whole of the room or operating theatre-needs to be designated a laser controlled area, and staffworking or-moving within that area need protection.
These immediate risks are straightforward to define. We know far less about possible risks to laser operators from long term use. Some anecdotal evidence suggests that ophthalmologists who spend many hours a week using a laser may have reduced central visual acuity, abnormal colour perception, and other features indicating possible macular damage. Possibly some of the early apparatus exposed doctors to risk through inadequate shielding, but this is not so for the modem laser. Nevertheless, a young ophthalmologist may expect to spend 40 years in photocoagulating procedures, and we do not know whether he is exposing himself to risk. There may be a case for screening, at regular intervals, all those surgeons intending to use lasers frequently. At least they sho-uld be well placed to provide such screening facilities.
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